Interferon- -2b/ribavirin vs monotherapy in hepatitis C

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.322, 2001-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon-α-2b/ribavirin: Exacerbation of hepatitis C-induced subclinical hypoadrenalism: case report

Reactions Weekly, Vol. 1, Iss. 1226, 2008-01 ,pp. : 16-17

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Sullivan S.D.

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Arguedas M.

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 477-479

Adis International

Access to resources Recommend Favorite

Interferon- -2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C

By Scott L.J. Perry C.M.

Drugs, Vol. 62, Iss. 3, 2002-01 ,pp. : 507-556

Adis International

Access to resources Recommend Favorite

Interferon-α-2b/ribavirin: Dermatitis herpetiformis: case report

Reactions Weekly, Vol. 1, Iss. 1013, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite